New Delhi, July 17, 2024.
Zydus Lifesciences on Wednesday said it has inked a licensing pact with Takeda to market a drug for the treatment of gastroesophageal reflux disease (GERD).
The company has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India, the drug firm said in a statement.
The drug will be marketed under the brand name Vault in the country, it added.